Pfizer’s Xeljanz Could See Narrower Label And New REMS Due To CV And Malignancy Risks

 
• By Sue Sutter
x-ray hands, rheumatoid arthritis
A Xeljanz study in high-risk rheumatoid arthritis patients has raised safety concerns. • Source: Shutterstock

More from United States

More from North America